GlassScriptPhysician profile
Jose A Mora
NPI 1235206467
$1,201.69
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $228 · 2020: $134 · 2021: $181 · 2022: $144 · 2023: $177 · 2024: $337.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $515.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $514.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $410.53 | 2019-2024 | Farxiga, Lokelma |
| Boehringer Ingelheim Pharmaceuticals, INC. | $173.74 | 2019-2024 | Jardiance, Tradjenta, Synjardy |
| Bayer Healthcare Pharmaceuticals INC. | $125.00 | 2024 | |
| Pbg Puerto Rico LLC | $119.11 | 2019-2023 | |
| Eli Lilly Export S.A. Puerto Rico Branch | $96.04 | 2021-2023 | Trulicity, Mounjaro |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $74.39 | 2019 | |
| Gilead Sciences, INC. | $61.16 | 2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $45.89 | 2022 | |
| Pfizer INC. | $33.03 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $24.88 | 2021 | |
| Merck Sharp & Dohme LLC | $23.39 | 2024 | Capvaxive |
| Pfizer Pharmaceuticals LLC | $14.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Mora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.